• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005:55:74108.
  • 2
    Dueñas-González A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005;4:124.
  • 3
    Muñoz N, Bosch FX, De Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:51827.
  • 4
    Bulkmans NW, Rozendaal L, Voohorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92:18002.
  • 5
    Wright Jr TC, Schiffman M, Solomon D et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. ACOG 2004;103:3049.
  • 6
    Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening. Arch Pathol Lab Med 2003;127:95968.
  • 7
    Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by novel quantitative real-time PCR technique. J Clin Microbiol 2002;40:88691.
  • 8
    Lörincz AT, Castle PE, Sherman ME et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. THE LANCET 2002;360:2289.
  • 9
    Gravitt PE, Burk RD, Lorincz A et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. CEBP 2003;12:47784.
  • 10
    Dalstein V, Riethmuller D, Prétet JL et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396403.
  • 11
    Joseffson AM, Magnusson PK, Ylitalo N. A higher level of human papillomavirus 16 DNA was associated with an increased risk for cervical carcinoma in situ. EBM 2001;6:29.
  • 12
    Ylitalo N, Sorenson P, Josefsson AM. Persistently high loads of human papillomavirus 16 over time were associated with an increased risk for cervical cancer. EBM 2001;6:30.
  • 13
    Josefsson AM, Magnusson PKE, Ylitalo N et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. THE LANCET 2000;355:218993.
  • 14
    Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL. Dynamics of HPV 16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006;35:2707.
  • 15
    Casas L, Galvan SC, Ordonez RM, Lopez N, Guido M, Berumen J. Asian-American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int J Cancer 1999;83:44955.
  • 16
    Crusius K, Auvinen E, Alonso A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997;16:143744.
  • 17
    Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987;61:96271.
  • 18
    Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increase viral immortalization capacity. Proc Natl Acad Sci USA 1992;89:315963.
  • 19
    Howley PM, Sceffner M, Huibregtse J, Munger K. Oncoproteins encoded by the cancer-associated human papillomaviruses target the products of the retinoblastoma and p53 tumor suppressor genes. Cold Spring Harb Symp Quant Biol 1991;56:14955.
  • 20
    Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). BJC 2005;92:2195200.
  • 21
    Kulmala S-MA, Syrjänen SM, Gyllensten UB et al. Early integration of high copy HPV 16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 2006;59:5137.
  • 22
    Garbar C, Mascaux C, Fontaine V. Efficiency of an inexpensive liquid-based cytology performed by cytocentrifugations: a comparative study using the histology as reference standard. CytoJournal 2005;2:15.
  • 23
    Fujii T, Masmoto N, Saito M et al. Comparison between in situ hybridization and real-time PCR technique as a means of detecting the integrated form of human papillomavirus 16 in cervical neoplasia. Diagn Mol Pathol 2005;14:1038.
  • 24
    Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol 1991;72:103944.
  • 25
    Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA residual material from Thinprep papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002;8:2199210.
  • 26
    Masmoto N, Fujii T, Ishikawa I et al. Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients. Gynecol Oncol 2004;94:50914.
  • 27
    Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H. Detection and typing of multiple genital human papillomavirus by DNA amplification with consensus primers. Jpn J Cancer Res 1991;82:52431.
  • 28
    Munoz N, Kato I, Bosch FX et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:50410.
  • 29
    Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste. Costa Rica. J Infect Dis 2005;191:180816.
  • 30
    Kulasingam SL, Hughes JP, Kiviat NB et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. JAMA 2002;288:174957.
  • 31
    Ylitalo N, Josefsson A, Melbye M et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000;60:602732.
  • 32
    Nagao S, Yoshinouchi M, Miyagi Y et al. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. J Clin Microbiol 2002;40:8637.
  • 33
    Wagatsuma M, Hashimoto K, Matsukura T. Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flaking sequences. J Virol 1990;64:81321.